Ivo Francischetti and Colleagues on Glycoprotein VI Contributing to Platelet Activation in HIT
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Glycoprotein VI is a receptor for the PF4/anti-PF4 IgG complex and contributes to platelet activation in heparin-induced thrombocytopenia (HIT)
By Ivo Francischetti, Kathryn Dane, Ed Galgo, Michael B. Streiff, and John F. Andersen
Heparin-induced thrombocytopenia (HIT) involves platelet activation by PF4/anti-PF4 complexes.
This study identifies glycoprotein VI (GPVI) as a receptor for these complexes, enhancing PF4 binding (Kd ≈ 30–100 nM) and platelet aggregation via FcγRIIA.
GPVI blockade (anti-GPVI antibodies, ACT017) suppressed activation, while AlphaFold modeling revealed electrostatic interactions between GPVI and PF4/IgG.
These findings position GPVI as a potential therapeutic target in HIT.”
Read the full article in JTH.
Article: Glycoprotein VI is a receptor for the PF4/anti-PF4 IgG complex and contributes to platelet activation in heparin-induced thrombocytopenia (HIT)
Authors: Ivo Francischetti, Kathryn Dane, Ed Galgo, Michael Streiff, John Andersen

Stay updated on all scientific advances with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies